Kuros Biosciences Ltd.

Environmental & Social Information • Sep 7, 2010

News Details

Corporate | 7 September 2010 17:45

Cytos Biotechnology to Present at the 2010 Annual Conference of the European Respiratory Society in Barcelona, Spain

Cytos Biotechnology AG / Key word(s): Miscellaneous

07.09.2010 17:45

Publication of a media release

Schlieren (Zurich), Switzerland, September 7, 2010 - Cytos Biotechnology
Ltd (SIX:CYTN) today announced that PD Dr. med. Kai-Michael Beeh, principal
investigator, will present late breaking abstract no. 7082 'TLR9 agonist
CYT003-QbG10 is safe and efficacious in persistent allergic asthma: A
double-blind, placebo-controlled phase II study' at the 2010 Annual
Conference of the European Respiratory Society in Barcelona, Spain. The
presentation will take place on Tuesday, September 21, 2010 in Session 360
(10:45-12:45) in Hall 3, starting at approximately 11:45am.

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 78 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner@cytos.com
Website: www.cytos.com

07.09.2010 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in München, Berlin, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX

End of Announcement EquityStory News-Service

---